An Experimental System for the Evaluation of Retroviral Vector Design to Diminish the Risk for Proto-oncogene Activation

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2007 Nov 10

PMID 17991809

Citations 54

Authors

Byoung Y Ryu

Marguerite V Evans-Galea

John T Gray

David M Bodine

Derek A Persons

Arthur W Nienhuis

Affiliations

Soon will be listed here.

Abstract

Pathogenic activation of the LMO2 proto-oncogene by an oncoretroviral vector insertion in a clinical trial for X-linked severe combined immunodeficiency (X-SCID) has prompted safety concerns. We used an adeno-associated virus vector to achieve targeted insertion of a gamma-retroviral long terminal repeat (LTR) driving a GFP expression cassette with flanking loxP sites in a human T-cell line at the precise location of vector integration in one of the patients with X-SCID. The LTR-GFP cassette was inserted into the first intron of the LMO2 gene, resulting in strong activation of LMO2. Cre-mediated cassette exchange was used to replace the original LTR-GFP cassette with one flanked by insulator elements leading to a several fold reduction in LMO2 expression. The LTR-GFP cassette was also replaced with a globin gene regulatory cassette that failed to activate the LMO2 gene in lymphoid cells. A gamma-retroviral vector with 2 intact LTRs resulted in activation of the LMO2 gene when inserted into the first intron, but a self-inactivating lentiviral vector with an internal cellular promoter and flanking insulator elements did not activate the LMO2 gene. Thus, this system is useful for comparing the safety profiles of vector cassettes with various regulatory elements for their potential for proto-oncogene activation.

Citing Articles

Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.

Segura E, Ayoub P, Hart K, Kohn D Viruses. 2023; 15(3).

PMID: 36992422 PMC: 10054523. DOI: 10.3390/v15030713.

Extracellular Vesicles and Their Use as Vehicles of Immunogens.

Chiozzini C, Ridolfi B, Federico M Methods Mol Biol. 2022; 2504:177-198.

PMID: 35467287 DOI: 10.1007/978-1-0716-2341-1_13.

High level of fetal-globin reactivation by designed transcriptional activator-like effector.

Zhan J, Irudayam M, Nakamura Y, Kurita R, Nienhuis A Blood Adv. 2020; 4(4):687-695.

PMID: 32084259 PMC: 7042981. DOI: 10.1182/bloodadvances.2019000482.

Determination of the Membrane Transport Properties of Jurkat Cells with a Microfluidic Device.

Yang T, Peng J, Shu Z, K Sekar P, Li S, Gao D Micromachines (Basel). 2019; 10(12).

PMID: 31795446 PMC: 6952789. DOI: 10.3390/mi10120832.

Barcoding of Macaque Hematopoietic Stem and Progenitor Cells: A Robust Platform to Assess Vector Genotoxicity.

Yabe I, Truitt L, Espinoza D, Wu C, Koelle S, Panch S Mol Ther Methods Clin Dev. 2018; 11:143-154.

PMID: 30547048 PMC: 6258888. DOI: 10.1016/j.omtm.2018.10.009.

References

Shou Y, Ma Z, Lu T, Sorrentino B . Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A. 2006; 103(31):11730-5. PMC: 1518804. DOI: 10.1073/pnas.0603635103. View

Hammond S, Crable S, Anderson K . Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia. Leuk Res. 2004; 29(1):89-97. DOI: 10.1016/j.leukres.2004.05.013. View

Ott M, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12(4):401-9. DOI: 10.1038/nm1393. View

Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A . Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002; 296(5577):2410-3. DOI: 10.1126/science.1070104. View

Nienhuis A . Assays to evaluate the genotoxicity of retroviral vectors. Mol Ther. 2006; 14(4):459-60. DOI: 10.1016/j.ymthe.2006.08.003. View

Check E . Gene therapy put on hold as third child develops cancer. Nature. 2005; 433(7026):561. DOI: 10.1038/433561a. View

Blaese R, Culver K, Miller A, Carter C, Fleisher T, Clerici M . T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science. 1995; 270(5235):475-80. DOI: 10.1126/science.270.5235.475. View

Royer-Pokora B, Rogers M, Zhu T, Schneider S, Loos U, Bolitz U . The TTG-2/RBTN2 T cell oncogene encodes two alternative transcripts from two promoters: the distal promoter is removed by most 11p13 translocations in acute T cell leukaemia's (T-ALL). Oncogene. 1995; 10(7):1353-60. View

Hanawa H, Hargrove P, Kepes S, Srivastava D, Nienhuis A, Persons D . Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia. Blood. 2004; 104(8):2281-90. DOI: 10.1182/blood-2004-03-0863. View

10.

Bank A, Dorazio R, Leboulch P . A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann N Y Acad Sci. 2005; 1054:308-16. DOI: 10.1196/annals.1345.007. View

11.

Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, de Villartay J . Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002; 346(16):1185-93. DOI: 10.1056/NEJMoa012616. View

12.

Emery D, Yannaki E, Tubb J, Stamatoyannopoulos G . A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci U S A. 2000; 97(16):9150-5. PMC: 16837. DOI: 10.1073/pnas.160159597. View

13.

Hanawa H, Persons D, Nienhuis A . High-level erythroid lineage-directed gene expression using globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and murine hematopoietic cells. Hum Gene Ther. 2002; 13(17):2007-16. DOI: 10.1089/10430340260395866. View

14.

Miller D, Wang P, Petek L, Hirata R, Sands M, Russell D . Gene targeting in vivo by adeno-associated virus vectors. Nat Biotechnol. 2006; 24(8):1022-6. DOI: 10.1038/nbt1231. View

15.

Nathwani A, Gray J, Ng C, Zhou J, Spence Y, Waddington S . Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood. 2005; 107(7):2653-61. PMC: 1895379. DOI: 10.1182/blood-2005-10-4035. View

16.

Gaspar H, Parsley K, Howe S, King D, Gilmour K, Sinclair J . Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004; 364(9452):2181-7. DOI: 10.1016/S0140-6736(04)17590-9. View

17.

Kohn D, Hershfield M, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska E . T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med. 1998; 4(7):775-80. PMC: 3777239. DOI: 10.1038/nm0798-775. View

18.

Ramezani A, Hawley T, Hawley R . Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood. 2003; 101(12):4717-24. DOI: 10.1182/blood-2002-09-2991. View

19.

Yu S, von Ruden T, Kantoff P, Garber C, Seiberg M, Ruther U . Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci U S A. 1986; 83(10):3194-8. PMC: 323479. DOI: 10.1073/pnas.83.10.3194. View

20.

Gaszner M, Felsenfeld G . Insulators: exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet. 2006; 7(9):703-13. DOI: 10.1038/nrg1925. View